EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Addressing the Research and Development Gaps in Modern Phage Therapy

Paul E. Turner, Joana Azeredo, Ed T. Buurman, Sabrina Green, Jakob Krause Haaber, Douglas Haggstrom, Koichi Kameda de Figueiredo Carvalho, Claas Kirchhelle, Mercedes Gonzalez Moreno, Jean-Paul Pirnay, Mirza Alas Portillo

PHAGE: Therapy, Applications, and Research · 2024-03-01 · 5 (1) · 30-39

DOI: 10.1089/phage.2023.0045 ↗
AbstractBibliografische Angaben

Abstract

Antimicrobial resistance is on the rise globally, prompting increased research and development (R&D) of phage therapy as a strategy to address difficult-to-treat bacterial infections. We review the current state of phage therapy research, including major operational, epistemic, and biological challenges for phage R&D, and discuss some new approaches to developing the technology motivated by recent breakthroughs such as artificial intelligence and synthetic phage production. In addition, we contextualize these R&D challenges and opportunities in light of the ongoing predicament of commercial antimicrobial innovation and current public–private efforts to reinvigorate the pipeline of antimicrobial drug discovery. We conclude with reflections on the potential for new phage therapies to be readily accessible across all income contexts to better ensure broad patient access, and consider possible alternatives to current public and public–private solutions for phage therapy and production.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →